Pangolin Therapeutics
1 known investors
Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.
Founders & leadership
EA
Enrique Alvarez SotomayorCo-Founder and CEO
AM
Andrew MirankerCo-Founder, Scientific Advisory Board Chair
Investors · 1
Competitors · 6
by search overlap
PanTher Therapeutics6 shared keywordsPanTher develops targeted cancer therapeutics that deliver drugs directly to tumor sites at high concentrations over extended periods, aiming to improve clinical outcomes while reducing side effects. The platform is designed to be applicable across multiple therapeutic types for oncology treatment.
Palvellatx5 shared keywordsPalvella Therapeutics develops QTORIN™, a targeted topical formulation of rapamycin designed to treat rare skin diseases including microcystic lymphatic malformations and cutaneous venous malformations by delivering the active ingredient to the dermal layers with minimal systemic absorption.
Paradigm Therapeutics4 shared keywordsParadigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.
Palm Therapeutics4 shared keywordsPalm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules. The company focuses on modulating protein palmitoylation, a post-translational modification involved in multiple disease pathways.
Pliant Therapeutics4 shared keywordsPliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics to treat serious diseases. The company focuses on understanding integrin biology and molecular mechanisms of pathology to create safer and more effective therapies for patients.
Pannextherapeutics3 shared keywordsPannex Therapeutics is developing Pannexin 1 (Panx1) channel blockers, a drug platform targeting pathological ATP release that drives neuroinflammation and immune dysregulation. Its therapeutics address unmet medical needs in neurology and oncology.
Companies competing with Pangolin Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Pangolin Therapeutics do?
- Pangolin Therapeutics develops Pangomers, synthetic molecules designed to target and interfere with intrinsically disordered proteins involved in Type 2 Diabetes, neurodegeneration, and cancer. The company uses molecular modeling and drug discovery tools to create therapeutics for previously undruggable protein targets.
- Who founded Pangolin Therapeutics?
- Pangolin Therapeutics was founded by Enrique Alvarez Sotomayor, Andrew Miranker.
- Who are Pangolin Therapeutics's investors?
- Pangolin Therapeutics's investors include Connecticut Innovations.